Effects of anti-C5a monoclonal antibodies on oxygen use in a porcine model of severe sepsis

European Journal of Clinical Investigation

Volumn 28, Issue 3, 1998, Pages 227-234

  Mohr, M ^a,b   Hopken U ^a   Oppermann, M ^a   Mathes, C ^a   Goldmann, K ^a   Siever, S ^a   Gotze O ^a   Burchardi, H ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b University of Goettingen ^*  (Germany)

Author keywords

C5a; Cobra venom factor; Complement; Lactate; Oxygen consumption; Oxygen use; Sepsis; Septic shock

Indexed keywords

COBROTOXIN; COMPLEMENT COMPONENT C5A; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ESCHERICHIA COLI; GRAM NEGATIVE SEPSIS; HEART INJURY; HEMODYNAMICS; HYPERLACTATEMIA; HYPOTENSION; LACTATE BLOOD LEVEL; NONHUMAN; OXYGEN CONSUMPTION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SWINE; TACHYCARDIA;

ANIMALS; ANTIBODIES, MONOCLONAL; BACTEREMIA; BLOOD PRESSURE; COBRA VENOMS; COMPLEMENT C5A; DISEASE MODELS, ANIMAL; ENDOTOXINS; ESCHERICHIA COLI INFECTIONS; HEMODYNAMIC PROCESSES; LACTIC ACID; OXYGEN CONSUMPTION; SEPSIS; SWINE; VASCULAR RESISTANCE;

EID: 0031982250     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.1998.00260.x     Document Type: Article

References (32)

1. Parillo JE. Pathogenetic mechanisms of septic shock. N Engl J Med 1993; 328: 1471-7.
2. Parrillo JE. Septic shock in humans: advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy. Ann Intern Med 1990; 113: 227-42.
3. Thijs LG, Schneider AJ, Groeneveld ABJ. The haemodynamics of septic shock. Intensive Care Med 1990; 16 (Suppl. 3): S182-S6.
4. Bone RC. Sepsis and its complications: The clinical problem. Crit Care Med 1994; 22: S8-S11.
5. Menger MD, Vollmar B, Messmer K. Sepsis and nutritional blood flow. In: Reinhart K, Eyrich K, Spring C, eds. Sepsis Current Perspectives in Patlwpliysiology and Therapy. Berlin: Springer, 1994: 163-73.
6. Bone RC. Inhibitors of complement and neutrophils: A critical evaluation of their role in the treatment of sepsis. Crit Care Med 1992; 20: 891-8.
7. de Boer JP, Wolbink GJ, Thijs LG, Baars JW, WagstafTJ, Hack CE. Interplay of complement and cytokines in the pathogenesis of septic shock. Immunopharmacology 1992; 24: 135-418.
8. de Boer JP, Creasey AA, Chang A et al. Activation of the complement system in Baboons challenged with live Escherichia coli: correlation with mortality and evidence for a biphasic activation pattern. Infect Immun 1993; 61: 4293430.
9. Padalino P, Gardinali M, Pallavicini J, Chiara O, Bisiani G, Nespoli A. Complement activation and endotoxin in sepsis. Prog Clin Bid Res 1989; 308: 277-82.
10. Frank MM. Complement in the pathophysiology of human disease. N Engl J Med 1987; 316: 1525-30.
11. Hugli TE. Biochemistry and biology of anaphylatoxins. Complement 1986; 3: 111-27.
12. Vogt W. Anaphylatoxins: Possible roles in diseases. Complement 1986; 3: 177-88.
13. Lundberg C, Marceau F, Hugli TE. C5a induced hemodynamic and hematological changes in the rabbit: role of cyclooxygenase products and polymorphnuclear leukocytes. Am J Pathol 1987; 128: 471-83.
14. Pavek K, Piper PJ, Smedegard G. Anaphylatoxin-induced shock and two patterns of anaphylatoxic shock. Hemodynamics and mediators. Ada Physiol Scand 1979; 105: 393-403.
15. Smedegard G, Cui L, Hugli TE. Endotoxin-induced shock in the rat. A role for C5a. Am J Pathol 1989; 135: 489-97.
16. Stevens JH, O'Hanley P, Shapiro JM et al. Effects of anti-C5a antibodies on the adult respiratory distress syndrome in septic primates. J Clin Invest 1986; 77: 1812-16.
17. Borg T, Alvfors A, Gerdin B, Modig J. A porcine model of early adult respiratory distress syndrome induced by endotoxaemia. 1985; 29: 814-30.
18. Dehring DJ, Steinberg SM, Wismar BL, Lowery BD, Carey LC, Cloutier CT. Complement depletion in a porcine model of septic acute respiratory disease. J Trauma 1987; 27: 61525.
19. Hosea S, Brown E, Hammer C, Frank M. Role of complement activation in a model of adult respiratory distress syndrome. J Clin Invest 1980; 66: 375-82.
20. Höpken U, Mohr M, Strubner A et al. Inhibition of interleukin-6 synthesis in an animal model of septic shock by anti-C5a monoclonal antibodies. Eur J Immunol 1996; 26: 1103-9.
21. Höpken U, Strüber A, Oppermann M, Mohr M, Mücke KH, Burchardi H, Götze O. Production and characterization of peptide-specific monoclonal antibodies that recognize a neoepitope on hog C5a. In: Faist E, Meakins J, Schildberg FW, eds. Host Defense Dysfunction in Trauma, Shock and Sepsis. Berlin: Springer, 1993; 411-17.
22. Niemer M, Nemes C, Lundsgaard-Hansen P, Blauhut B. Datenbiich Intensivmedizin, 3rd edn. Stuttgart: Gustav Fischer, 1992.
23. Vogel CW, Müller-Eberhardt HJ. Cobra venom factor: improved method for purification and biochemical characterization. J Immunol Methods 1984; 73: 203-20.
24. Oppermann M, Höpken U, Götze O. Assessment of complement activation HI vivo. Iinmnnopharmacology 1992; 24: 119-34.
25. Cain SM. Peripheral oxygen uptake and delivery in health and disease. Clinical Chest Med 1983; 4: 139-48.
26. Schumacker PT, Cain SM. The concept of a critical oxygen delivery. Intensive Care Med 1987; 13: 223-9.
27. Cain SM. A current view of oxygen supply dependency. In: Reinhart K, Eyrich K, Spring C, eds. Sepsis - Current Perspectives in Pathopliysiology and Therapy. Berlin: Springer, 1994: 150-62.
28. Rashkin MC, Bosken C, Baugham RP. Oxygen delivery in critically ill patients. Relationship to blood lactate and survival. Chest 1985; 87: 580-4.
29. Reinhart K, Hannemann L, Meier-Hellmann A, Specht M. Monitoring of O2 transport and tissue oxygénation in septic. shock. In: Reinhart K, Eyrich K, Spring C, eds. Sepsis Current Perspectives in Pathopliysiology and Therapy. Berlin: Springer, 1994: 193-213.
30. Gutierrez G. Sepsis and cellular metabolism. In: Reinhart K, Eyrich K, Spring C, eds. Sepsis - Current Perspccthvs in Pathopliysiology and Therapy. Berlin: Springer, 1994: 181-90.
31. Chenoweth DE. The properties of human C5a anaphylatoxin. Contrib Nephrol 1987; 59: 51-71.
32. Hugli TE, Marceau F, Lundberg C. Effect of complement fragments on pulmonary and vascular smooth muscle. Am Rev Respir Dis 1987; 135: S9-S13.